MHUA
Meihua International Medical Technologies Co., Ltd.
Medical - Instruments & Supplies
Market Cap$2M
5Y Perf.-99.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MHUA vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-68.0%
MHUA vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MHUA | XTLB |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $2M | $294K |
| Revenue (TTM) | $184M | $451K |
| Net Income (TTM) | $19M | $-1M |
| Gross Margin | 33.6% | 26.4% |
| Operating Margin | 12.6% | -481.6% |
| Forward P/E | 0.2x | — |
| Total Debt | $8M | $138K |
| Cash & Equiv. | $16M | $371K |
MHUA vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MHUA
XTLB
| Stock | Feb 22 | Apr 26 | Return |
|---|---|---|---|
| Meihua Internationa… (MHUA) | 100 | 0.9 | -99.1% |
| XTL Biopharmaceutic… (XTLB) | 100 | 32.0 | -68.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MHUA vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MHUA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MHUA
Meihua International Medical Technologies Co., Ltd.
The Growth Leader
MHUA carries the broadest edge in this set and is the clearest fit for growth and quality.
- -0.2% revenue growth vs XTLB's -173.2%
- 10.1% margin vs XTLB's -227.7%
- 9.7% ROA vs XTLB's -17.7%, ROIC 7.4% vs -54.1%
Best for: growth and quality
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.71
- EPS growth 45.5%
- -87.3% 10Y total return vs MHUA's -99.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MHUA | -0.2% revenue growth vs XTLB's -173.2% |
| Quality / Margins | MHUA | 10.1% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs MHUA's 2.86, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -50.9% vs MHUA's -73.6% |
| Efficiency (ROA) | MHUA | 9.7% ROA vs XTLB's -17.7%, ROIC 7.4% vs -54.1% |
MHUA vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMHUALAGGINGXTLB
XTLBXTL Biopharmaceutical…
2leads
MHUAMeihua International …
3leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MHUA4/5
Valuation MetricsMultiples, price ratios, and targets
MHUA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MHUA7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB5/6
Risk & VolatilityBeta, volatility, and downside exposure
XTLB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MHUA leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
MHUA is the larger business by revenue, generating $184M annually — 407.5x XTLB's $451,000. MHUA is the more profitable business, keeping 10.1% of every revenue dollar as net income compared to XTLB's -2.3%.
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $184M | $451,000 |
| EBITDAEarnings before interest/tax | $24M | -$1M |
| Net IncomeAfter-tax profit | $19M | -$1M |
| Free Cash FlowCash after capex | $12M | $0 |
| Gross MarginGross profit ÷ Revenue | +33.6% | +26.4% |
| Operating MarginEBIT ÷ Revenue | +12.6% | -4.8% |
| Net MarginNet income ÷ Revenue | +10.1% | -2.3% |
| FCF MarginFCF ÷ Revenue | +6.6% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -35.8% | +20.0% |
MHUA leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
MHUA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $2M | $293,767 |
| Enterprise ValueMkt cap + debt − cash | -$6M | $60,767 |
| Trailing P/EPrice ÷ TTM EPS | 0.19x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -0.40x | — |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.65x |
| Price / BookPrice ÷ Book value/share | 0.01x | 0.05x |
| Price / FCFMarket cap ÷ FCF | 0.14x | — |
MHUA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
MHUA leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
MHUA delivers a 11.2% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-26 for XTLB. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to MHUA's 0.05x. On the Piotroski fundamental quality scale (0–9), MHUA scores 4/9 vs XTLB's 3/9, reflecting mixed financial health.
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +11.2% | -25.5% |
| ROA (TTM)Return on assets | +9.7% | -17.7% |
| ROICReturn on invested capital | +7.4% | -54.1% |
| ROCEReturn on capital employed | +9.4% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.05x | 0.03x |
| Net DebtTotal debt minus cash | -$8M | -$233,000 |
| Cash & Equiv.Liquid assets | $16M | $371,000 |
| Total DebtShort + long-term debt | $8M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | 31.87x | -13.31x |
MHUA leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,963 today (with dividends reinvested), compared to $59 for MHUA. Over the past 12 months, XTLB leads with a -50.9% total return vs MHUA's -73.6%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs MHUA's -71.3% — a key indicator of consistent wealth creation.
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +271.2% | +11.3% |
| 1-Year ReturnPast 12 months | -73.6% | -50.9% |
| 3-Year ReturnCumulative with dividends | -97.6% | -45.7% |
| 5-Year ReturnCumulative with dividends | -99.4% | -80.4% |
| 10-Year ReturnCumulative with dividends | -99.4% | -87.3% |
| CAGR (3Y)Annualised 3-year return | -71.3% | -18.4% |
XTLB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
XTLB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than MHUA's 2.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 26.0% from its 52-week high vs MHUA's 11.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.86x | 1.71x |
| 52-Week HighHighest price in past year | $64.00 | $10.28 |
| 52-Week LowLowest price in past year | $2.05 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +11.9% | +26.0% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 1K | 2.4M |
XTLB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MHUAMeihua Internatio… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MHUA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). XTLB leads in 2 (Total Returns, Risk & Volatility).
Best OverallMeihua International Medica… (MHUA)Leads 3 of 6 categories
Loading custom metrics...
MHUA vs XTLB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is MHUA or XTLB a better buy right now?
Meihua International Medical Technologies Co.
, Ltd. (MHUA) offers the better valuation at 0. 2x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MHUA or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -80. 4%, compared to -99. 4% for Meihua International Medical Technologies Co. , Ltd. (MHUA). Over 10 years, the gap is even starker: XTLB returned -87. 3% versus MHUA's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MHUA or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus Meihua International Medical Technologies Co. , Ltd. 's 2. 86β — meaning MHUA is approximately 68% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 5% for Meihua International Medical Technologies Co. , Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — MHUA or XTLB?
Meihua International Medical Technologies Co.
, Ltd. (MHUA) is the more profitable company, earning 11. 2% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 11. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MHUA leads at 14. 8% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — MHUA leads at 34. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MHUA or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MHUA or XTLB better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Meihua International Medical Technologies Co. , Ltd. (MHUA) carries a higher beta of 2. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -87. 3%, MHUA: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MHUA and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MHUA is a small-cap deep-value stock; XTLB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.